Artradol 100 mg lyophilisate for solution preparation, 10 ampoules

Degenerative-dystrophic diseases of the joints and spine; primary arthrosis, osteoarthritis with predominant involvement of large joints, intervertebral osteochondrosis.

Intramuscularly, 100 mg every other day.
Before use, dissolve the contents of the ampoule in 1 ml of water for injection.
In case of good tolerance, the dose is increased to 200 mg starting from the 4th injection.
The treatment course consists of 25-35 injections.
A repeat course can be conducted after 6 months.
The duration of repeat treatment courses is determined by the physician.

One ampoule contains:
Sodium chondroitin sulfate (calculated as 100% dry substance of sodium chondroitin sulfate) - 100 mg.

White or white with a yellowish tint porous, compacted tablet mass.

Increased sensitivity; pediatric age (efficacy and safety not established).
With caution:
Bleeding and tendency to bleed; thrombophlebitis. Pregnancy; lactation period.

Allergic reactions; hemorrhages at the injection site.

Possible enhancement of the action of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood coagulation parameters when used together.

Chondroitin sulfate is the main component of proteoglycans, which together with collagen fibers form the cartilage matrix. It has chondroprotective properties; inhibits the activity of enzymes that cause degradation of articular cartilage; stimulates the production of proteoglycans by chondrocytes; enhances metabolic processes in cartilage and subchondral bone; influences phosphorus-calcium metabolism in cartilage tissue, stimulates its regeneration, and participates in the formation of the fundamental substance of bone and cartilage tissue. It possesses anti-inflammatory and analgesic properties, helps reduce the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane, and inhibits the secretion of leukotriene B4 and prostaglandin E2. The drug promotes the restoration of cartilage surfaces of joints, prevents the collapse of connective tissue; normalizes the production of synovial fluid, leading to improved joint mobility and reduced pain intensity. Due to its structural similarity to heparin, it may potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory pathways.

Chondroitin sulfate is easily absorbed when administered intramuscularly, with significant concentrations detected in the blood after 30 minutes and in the synovial fluid after 15 minutes. The maximum concentration is reached 1 hour after administration, after which the concentration of the drug slowly decreases over 2 days. The drug primarily accumulates in cartilage tissue (maximum concentration in articular cartilage is reached after 48 hours). It is excreted by the kidneys within 24 hours.